Biomérieux Inc. acquired Astute Medical Inc. last April for a scant $90 million. It markets the U.S. FDA-cleared Nephrocheck test for acute kidney injury (AKI) that it gained from the startup, which had previously been a partner under a deal dating back to 2015.